{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:53:59Z","timestamp":1785437639967,"version":"3.56.0"},"reference-count":229,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Phosphodiesterase 10A (PDE10A) is a dual-substrate enzyme that hydrolyzes both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), playing a critical role in regulating intracellular signaling pathways. While its function has been extensively studied in the central nervous system, emerging evidence highlights its broader physiological and pathological relevance, including its involvement in cancer. Functionally, it modulates key signaling pathways such as cAMP\/protein kinase A (PKA) and cGMP\/protein kinase G (PKG), influencing cell proliferation, differentiation, and apoptosis. In cancer, PDE10A exhibits a context-dependent role. It functions as an oncogene in cancers such as colorectal, ovarian, gastric, and non-small cell lung cancers through overexpression and downstream activation of the Wnt\/\u03b2-catenin, MAPK\/ERK, and PI3K\/AKT pathways. Pharmacological inhibition of PDE10A using selective inhibitors has demonstrated potent anti-tumor effects in preclinical models by restoring cyclic nucleotide levels and suppressing oncogenic signaling. Conversely, in glioblastoma (GBM), PDE10A acts as a tumor suppressor, and its knockdown promotes tumor progression via activation of the PI3K\/AKT pathway. These findings showed the ability of PDE10A to be considered as a promising biomarker and therapeutic target in oncology; however, it is suggested to examine the tissue-specific expression of PDE10A, baseline cyclic nucleotide levels, cross-talk with other pathways, differences in the degree and duration of PDE10A suppression, and the interplay between PDE10A-mediated cyclic nucleotide signaling and compensatory oncogenic pathways for an effective therapy as observed in other PDEs family reviewed in this manuscript.<\/jats:p>","DOI":"10.3389\/fonc.2025.1669157","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:16:51Z","timestamp":1760588211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["PDE10A as a novel diagnostic and therapeutic target in cancer: insights and challenges"],"prefix":"10.3389","volume":"15","author":[{"given":"Sahar","family":"Ghoflchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nakhaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Abbasinezhad-Moud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Jalili-Nik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Cimino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.1013","article-title":"Characterization and phosphorylation of PDE10A2, a novel alternative splice variant of human phosphodiesterase that hydrolyzes cAMP and cGMP","volume":"261","author":"Kotera","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"J Biol Chem"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.gene.2016.12.033","article-title":"Novel PDE10A transcript diversity in the human striatum: Insights into gene complexity, conservation and regulation","volume":"606","author":"MacMullen","year":"2017","journal-title":"Gene"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2020.1709444","article-title":"Phosphodiesterase 10 (PDE10) inhibitors: An updated patent review (2014-present)","volume":"30","author":"Zag\u00f3rska","year":"2020","journal-title":"Expert Opin Ther Patents"},{"key":"B5","doi-asserted-by":"publisher","first-page":"69264","DOI":"10.18632\/oncotarget.20566","article-title":"Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking \u03b2-catenin and MAPK signaling","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.94","article-title":"Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and \u03b2-catenin-dependent TCF transcriptional activity","volume":"34","author":"Li","year":"2015","journal-title":"Oncogene"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.OVCA15-A76","article-title":"Abstract A76: Targeting phosphodiesterase 10A for chemoprevention and treatment of ovarian cancer","volume":"22","author":"Silva","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.CRC16-A30","volume-title":"Novel non-COX inhibitory sulindac derivative with PDE10 inhibitory activity reduces incidence and multiplicity of colorectal adenomas in the APC plus\/min-FCCC mouse model","author":"Lee","year":"2017"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1158\/1538-7445.AM2017-5174","article-title":"Phosphodiesterase 10A inhibition as a novel approach to suppress \u03b2-catenin signaling in ovarian cancer cells","volume":"77","author":"Silva","year":"2017","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1940-6207.CAPR-21-0208","article-title":"Suppression of colon tumorigenesis in mutant Apc mice by a novel PDE10 inhibitor that reduces oncogenic \u03b2-Catenin","volume":"14","author":"Lee","year":"2021","journal-title":"Cancer Prev Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.18632\/oncotarget.6705","article-title":"\u03b2-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG","volume":"7","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13048-022-01050-9","article-title":"Phosphodiesterase 10A (PDE10A) as a novel target to suppress \u03b2-catenin and RAS signaling in epithelial ovarian cancer","volume":"15","author":"Borneman","year":"2022","journal-title":"J Ovarian Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2174\/1389450119666180808105056","article-title":"Advances in discovery of PDE10A inhibitors for CNS-related disorders. Part 1: overview of the chemical and biological research","volume":"20","author":"Jankowska","year":"2019","journal-title":"Curr Drug Targets"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddstr.2006.10.012","article-title":"Treating neuropsychiatric disorders with PDE10A inhibitors","volume":"3","author":"Siuciak","year":"2006","journal-title":"Drug Discov Today"},{"key":"B15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1210\/er.2013-1053","article-title":"Clinical and molecular genetics of the phosphodiesterases (PDEs)","volume":"35","author":"Azevedo","year":"2014","journal-title":"Endocrine Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00997-9","article-title":"Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders","volume":"26","author":"Delhaye","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2004.07.005","article-title":"A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases","volume":"15","author":"Zhang","year":"2004","journal-title":"Mol Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3321","article-title":"A subcellular map of the human proteome","volume":"356","author":"Thul","year":"2017","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cell.2018.06.021","article-title":"Molecular architecture of the mouse nervous system","volume":"174","author":"Zeisel","year":"2018","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2004.12.017","article-title":"Ca2+-calmodulin-dependent phosphodiesterase (PDE1): current perspectives","volume":"17","author":"Goraya","year":"2005","journal-title":"Cell signalling"},{"key":"B23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0079-6603(00)65001-8","article-title":"Cyclic nucleotide phosphodiesterases: relating structure and function","volume":"66","author":"Francis","year":"2000","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3551","article-title":"Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1) is a pharmacological target of differentiation-inducing factor-1, an antitumor agent isolated from Dictyostelium","volume":"64","author":"Shimizu","year":"2004","journal-title":"Cancer Res"},{"key":"B25","article-title":"Characterization of phosphodiesterase 1 in human Malignant melanoma cell lines","volume":"29","author":"Shimizu","year":"2009","journal-title":"Anticancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2010.08.015","article-title":"Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis","volume":"23","author":"Abusnina","year":"2011","journal-title":"Cell signalling"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2005.10.009","article-title":"Thymoquinone: a promising anti-cancer drug from natural sources","volume":"38","author":"Gali-Muhtasib","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"RP98903","DOI":"10.7554\/eLife.98903","article-title":"Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer","volume":"13","author":"Zhang","year":"2025","journal-title":"eLife"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22276","article-title":"Cyclic nucleotide phosphodiesterase-1C (PDE1C) drives cell proliferation, migration and invasion in glioblastoma multiforme cells in vitro","volume":"55","author":"Rowther","year":"2016","journal-title":"Mol carcinogenesis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13790","DOI":"10.1038\/s41598-024-64627-y","article-title":"PDE1B, a potential biomarker associated with tumor microenvironment and clinical prognostic significance in osteosarcoma","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B31","article-title":"The role of cyclic AMP in cell proliferation: a critical assessment of the evidence","volume":"15","author":"Boynton A","year":"1983","journal-title":"Advances in Cyclic Nucleotide Research"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.663778","article-title":"PDE2 inhibits PKA-mediated phosphorylation of TFAM to promote mitochondrial ca(2+)-induced colorectal cancer growth","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109862","article-title":"PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis","volume":"9","author":"Bernard","year":"2014","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13812","article-title":"Role of phosphodiesterase2A in proliferation and migration of human osteosarcoma cells","volume":"39","author":"Murata","year":"2019","journal-title":"Anticancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/cells12010068","article-title":"Low expression of phosphodiesterase 2 (PDE2A) promotes the progression by regulating mitochondrial morphology and ATP content and predicts poor prognosis in hepatocellular carcinoma","volume":"12","author":"Chen","year":"2023","journal-title":"Cells"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1984","article-title":"Identification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics","volume":"12","author":"De Waal","year":"2016","journal-title":"Nat Chem Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2017.10.032","article-title":"Targeting tumor cells based on Phosphodiesterase 3A expression","volume":"361","author":"Nazir","year":"2017","journal-title":"Exp Cell Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/s41598-017-02162-9","article-title":"PDE3 inhibitor and EGCG combination treatment suppress cancer stem cell properties in pancreatic ductal adenocarcinoma","volume":"7","author":"Kumazoe","year":"2017","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1233","article-title":"Phosphodiesterase 3A represents a therapeutic target that drives stem cell\u2013like property and metastasis in breast cancer","volume":"19","author":"Hao","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3176","article-title":"Integrated analysis using methylation and gene expression microarrays reveals PDE4C as a prognostic biomarker in human glioma","volume":"32","author":"Bao","year":"2014","journal-title":"Oncol Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.136","article-title":"Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF","volume":"32","author":"Pullamsetti","year":"2013","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.7150\/jca.24079","article-title":"PDE4a predicts poor prognosis and promotes metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"9","author":"Peng","year":"2018","journal-title":"J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2015.02.004","article-title":"The activity of cAMP-phosphodiesterase 4D7 (PDE4D7) is regulated by protein kinase A-dependent phosphorylation within its unique N-terminus","volume":"589","author":"Byrne","year":"2015","journal-title":"FEBS letters"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21478","article-title":"Downregulation of phosphodiesterase 4B (PDE4B) activates protein kinase A and contributes to the progression of prostate cancer","volume":"72","author":"Kashiwagi","year":"2012","journal-title":"Prostate"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-11-46","article-title":"Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model","volume":"11","author":"Tsunoda","year":"2012","journal-title":"Mol cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.62347\/TYOS8160","article-title":"PDE4B promotes the progression of gastric cancer via the PI3K\/AKT\/MYC pathway and immune infiltration","volume":"14","author":"Su","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.783050","article-title":"PDE4B induces epithelial-to-mesenchymal transition in bladder cancer cells and is transcriptionally suppressed by CBX7","volume":"9","author":"Huang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3208","article-title":"PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A","volume":"101","author":"Moon","year":"2003","journal-title":"Blood J Am Soc Hematology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0586-x","article-title":"PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells","volume":"50","author":"Sponziello","year":"2015","journal-title":"Endocrine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ccr.2011.01.004","article-title":"Hard times for oncogenic BRAF-expressing melanoma cells","volume":"19","author":"Houslay","year":"2011","journal-title":"Cancer Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2016.05.010","article-title":"Phosphodiesterase 5\/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway","volume":"378","author":"Liu","year":"2016","journal-title":"Cancer Letters"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00681","article-title":"Phosphodiesterase type 5 (PDE5) inhibitors sensitize topoisomerase II inhibitors in killing prostate cancer through PDE5-independent impairment of HR and NHEJ DNA repair systems","volume":"8","author":"Chang","year":"2019","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-013-1134-0","article-title":"Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells","volume":"31","author":"Li","year":"2014","journal-title":"Pharm Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2019.33.1_supplement.496.1","article-title":"Role of phosphodiesterase 5 (PDE5) in breast cancer stroma: implications for targeted therapy","volume":"33","author":"Barone","year":"2019","journal-title":"FASEB J"},{"key":"B55","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1186\/s12885-019-6152-9","article-title":"Repurposing mechanistic insight of PDE-5 inhibitor in cancer chemoprevention through mitochondrial-oxidative stress intervention and blockade of DuCLOX signalling","volume":"19","author":"Singh","year":"2019","journal-title":"BMC Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1900","article-title":"Expression and function of phosphodiesterase type 5 in human breast cancer cell lines and tissues: implications for targeted therapy","volume":"22","author":"Catalano","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1053\/j.gastro.2019.05.012","article-title":"Use of phosphodiesterase 5 inhibitors is associated with lower risk of colorectal cancer in men with benign colorectal neoplasms","volume":"157","author":"Huang","year":"2019","journal-title":"Gastroenterology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.23100","article-title":"Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance","volume":"36","author":"Chhonker","year":"2022","journal-title":"J Biochem Mol Toxicology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2051-1426-1-10","article-title":"Myeloid derived suppressor cells\u2013a new therapeutic target in the treatment of cancer","volume":"1","author":"Wesolowski","year":"2013","journal-title":"J immunotherapy cancer"},{"key":"B60","first-page":"41","article-title":"Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC","volume":"7","author":"Lin","year":"2017","journal-title":"Am J Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100541","article-title":"Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts","volume":"3","author":"Sharpe","year":"2022","journal-title":"Cell Rep Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1124\/mol.113.090043","article-title":"Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal\/genitourinary cancer cells","volume":"85","author":"Booth","year":"2014","journal-title":"Mol Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s42003-025-07519-9","article-title":"Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription","volume":"8","author":"Zhang","year":"2025","journal-title":"Commun Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12862-016-0695-z","article-title":"Evolution and expression of the phosphodiesterase 6 genes unveils vertebrate novelty to control photosensitivity","volume":"16","author":"Lagman","year":"2016","journal-title":"BMC Evolutionary Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3109\/07420528.2011.606945","article-title":"Testing the light-at-night (LAN) theory for breast cancer causation","volume":"28","author":"Stevens","year":"2011","journal-title":"Chronobiology Int"},{"key":"B66","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40170-023-00326-y","article-title":"Cone photoreceptor phosphodiesterase PDE6H inhibition regulates cancer cell growth and metabolism, replicating the dark retina response","volume":"12","author":"Yalaz","year":"2024","journal-title":"Cancer Metab"},{"key":"B67","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/cancers11030398","article-title":"The delta subunit of rod-specific photoreceptor cGMP phosphodiesterase (PDE6D) contributes to hepatocellular carcinoma progression","volume":"11","author":"Dietrich","year":"2019","journal-title":"Cancers"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.02.006","article-title":"High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma","volume":"37","author":"Fang","year":"2013","journal-title":"Leukemia Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806152105","article-title":"Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2986","article-title":"The tumor-suppressive microRNA-1\/133a cluster targets PDE7A and inhibits cancer cell migration and invasion in endometrial cancer","volume":"47","author":"Yamamoto","year":"2015","journal-title":"Int J Oncol"},{"key":"B71","article-title":"MiR-23b inhibits cell migration and invasion through targeting PDE7A in colon cancer cells","volume":"10","author":"Hao","year":"2017","journal-title":"Int J Clin Exp Pathol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107397","article-title":"PDE7B is a novel, prognostically significant mediator of glioblastoma growth whose expression is regulated by endothelial cells","volume":"9","author":"Brooks","year":"2014","journal-title":"PLoS One"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0499-2","article-title":"Phosphodiesterase 7B\/microRNA-200c relationship regulates triple-negative breast cancer cell growth","volume":"38","author":"Zhang","year":"2019","journal-title":"Oncogene"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.23.1_supplement.761.10","article-title":"Phosphodiesterase 7 (PDE7) and PDE4\/7 inhibitors kill chronic lymphocytic leukemia (CLL) cells via a cAMP-mitochondrial-dependent pathway","volume":"23","author":"Zahno","year":"2009","journal-title":"FASEB J"},{"key":"B75","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1186\/s12885-024-12364-w","article-title":"Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K\/AKT signaling pathway","volume":"24","author":"Du","year":"2024","journal-title":"BMC Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S259192","article-title":"Identification of PDE7B as a potential core gene involved in the metastasis of clear cell renal cell carcinoma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1303004110","article-title":"Phosphodiesterase-8A binds to and regulates Raf-1 kinase","volume":"110","author":"Brown","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2012.08.006","article-title":"Evaluation of PDE5 and PDE9 expression in benign and Malignant breast tumors","volume":"43","author":"Karami-Tehrani","year":"2012","journal-title":"Arch Med Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2184.2012.00819.x","article-title":"Inhibition of phosphodiestrase 9 induces c GMP accumulation and apoptosis in human breast cancer cell lines, MCF-7 and MDA-MB-468","volume":"45","author":"Saravani","year":"2012","journal-title":"Cell proliferation"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/1538-7445.AM2015-4372","article-title":"Phosphodiesterase 10A inhibition suppresses lung tumor cell growth by activating PKG to inhibit ras and Wnt signaling","volume":"75","author":"Zhu","year":"2015","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2275","article-title":"Phosphodiesterase 11A (PDE11A) gene defects in patients with ACTH-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors","volume":"97","author":"Vezzosi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1704","article-title":"Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype","volume":"96","author":"Lib\u00e9","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gm377","article-title":"Digital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survival","volume":"4","author":"Engstr\u00f6m","year":"2012","journal-title":"Genome Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.03.046","article-title":"Inhibitors of phosphodiesterase as cancer therapeutics","volume":"150","author":"Peng","year":"2018","journal-title":"Eur J medicinal Chem"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)68134-2","article-title":"Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues","volume":"257","author":"Martins","year":"1982","journal-title":"J Biol Chem"},{"key":"B86","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.3390\/ijms21207462","article-title":"Therapeutic implications for PDE2 and cGMP\/cAMP mediated crosstalk in cardiovascular diseases","volume":"21","author":"Sadek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0378-1119(97)00046-2","article-title":"Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3\u2032, 5\u2032-cyclic nucleotide phosphodiesterase","volume":"191","author":"Rosman","year":"1997","journal-title":"Gene"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2009.05.115","article-title":"Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte","volume":"136","author":"Norris","year":"2009","journal-title":"Development"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1201\/9781420020847.sece","article-title":"Role of PDEs in vascular health and disease: endothelial PDEs and angiogenesis","volume-title":"Cyclic nucleotide phosphodiesterases in health and disease","author":"Keravis","year":"2006"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/0898-6568(95)00042-N","article-title":"Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine","volume":"7","author":"Podzuweit","year":"1995","journal-title":"Cell signalling"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.156729","article-title":"Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling","volume":"331","author":"Masood","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.03.031","article-title":"Role of phosphodiesterase 2 in growth and invasion of human Malignant melanoma cells","volume":"26","author":"Hiramoto","year":"2014","journal-title":"Cell signalling"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2260","article-title":"Characterization of phosphodiesterase 2A in human Malignant melanoma PMP cells","volume":"29","author":"Morita","year":"2013","journal-title":"Oncol Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1995.75.4.725","article-title":"Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms","volume":"75","author":"Beavo","year":"1995","journal-title":"Physiol Rev"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M203647200","article-title":"Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes","volume":"277","author":"Wechsler","year":"2002","journal-title":"J Biol Chem"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2174\/138161210790963760","article-title":"Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs","volume":"16","author":"Keravis","year":"2010","journal-title":"Curr Pharm design"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6603(00)66031-2","article-title":"Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family","volume":"66","author":"Shakur","year":"2000","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.111.300003","article-title":"Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart","volume":"112","author":"Beca","year":"2013","journal-title":"Circ Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1312646","article-title":"Cyclic nucleotide phosphodiesterase 3 signaling complexes","volume":"44","author":"Ahmad","year":"2012","journal-title":"Hormone Metab Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-7-67","article-title":"Short term effects of milrinone on biomarkers of necrosis, apoptosis, and inflammation in patients with severe heart failure","volume":"7","author":"Lanfear","year":"2009","journal-title":"J Trans Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.13.10.6558-6571","article-title":"A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs","volume":"13","author":"Bolger","year":"1993","journal-title":"Mol Cell Biol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03622-6","article-title":"Keynote review: phosphodiesterase-4 as a therapeutic target","volume":"10","author":"Houslay","year":"2005","journal-title":"Drug Discov Today"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.4103\/2279-042X.167043","article-title":"A short review on structure and role of cyclic-3\u2019, 5\u2019-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool","volume":"4","author":"Eskandari","year":"2015","journal-title":"J Res Pharm practice"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1021\/tx000090l","article-title":"Cyclic 3 \u2018, 5 \u2018-nucleotide phosphodiesterases: potential targets for anticancer therapy","volume":"13","author":"Marko","year":"2000","journal-title":"Chem Res toxicology"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2011.02.015","article-title":"Treating brain tumors with PDE4 inhibitors","volume":"32","author":"Sengupta","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e09-01-0019","article-title":"Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4","volume":"20","author":"Kolosionek","year":"2009","journal-title":"Mol Biol Cell"},{"key":"B108","doi-asserted-by":"publisher","first-page":"7145198","DOI":"10.1155\/2019\/7145198","article-title":"PDE4 and Epac1 Synergistically Promote Rectal Carcinoma via the cAMP Pathway","volume":"2019","author":"Kong","year":"2019","journal-title":"Analytical Cell Pathology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.4161\/sgtp.2.1.15137","article-title":"Signaling of the direction-sensing FAK\/RACK1\/PDE4D5 complex to the small GTPase Rap1","volume":"2","author":"Serrels","year":"2011","journal-title":"Small GTPases"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1207","article-title":"Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B-cell Malignancies","volume":"23","author":"Kelly","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30325","article-title":"PDE4 inhibitor eliminates breast cancer stem cells via noncanonical activation of mTOR","volume":"123","author":"Mukherjee","year":"2022","journal-title":"J Cell Biochem"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1158\/1078-0432.CCR-17-2776","article-title":"Reactivation of cAMP pathway by PDE4D inhibition represents a novel druggable axis for overcoming tamoxifen resistance in ER-positive breast cancer","volume":"24","author":"Mishra","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.7150\/jca.35443","article-title":"High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma","volume":"10","author":"Liu","year":"2019","journal-title":"J Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"101377","DOI":"10.1016\/j.tranon.2022.101377","article-title":"PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK\/ERK signaling in a CRAF-dependent manner","volume":"19","author":"Cao","year":"2022","journal-title":"Trans Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.1999.00450.x","article-title":"Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases","volume":"262","author":"Kotera","year":"1999","journal-title":"Eur J Biochem"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.141614","article-title":"Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain","volume":"285","author":"Wang","year":"2010","journal-title":"J Biol Chem"},{"key":"B117","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0167-4889(01)00086-6","article-title":"Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain","volume":"1539","author":"Giordano","year":"2001","journal-title":"Biochim Biophys Acta (BBA)-Molecular Cell Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40139-015-0083-1","article-title":"Phosphodiesterase type 5 as a candidate therapeutic target in cancers","volume":"3","author":"Barone","year":"2015","journal-title":"Curr pathobiology Rep"},{"key":"B119","doi-asserted-by":"publisher","first-page":"13223","DOI":"10.18632\/oncotarget.14656","article-title":"Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome","volume":"8","author":"Cesarini","year":"2017","journal-title":"Oncotarget"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.03.172","article-title":"The association between phosphodiesterase type 5 inhibitors and prostate cancer: results from the REDUCE study","volume":"196","author":"Jamnagerwalla","year":"2016","journal-title":"J Urol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.10.016","article-title":"cGMP signaling increases antioxidant gene expression by activating forkhead box O3A in the colon epithelium","volume":"187","author":"Wang","year":"2017","journal-title":"Am J Pathology"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901212","article-title":"Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5","volume":"16","author":"Cote","year":"2004","journal-title":"Int J impotence Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.2001.4813","article-title":"Molecular organization of bovine rod cGMP-phosphodiesterase 6","volume":"310","author":"Tcheudji","year":"2001","journal-title":"J Mol Biol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.visres.2004.05.013","article-title":"Structural determinants of the PDE6 GAF A domain for binding the inhibitory \u03b3-subunit and noncatalytic cGMP","volume":"44","author":"Muradov","year":"2004","journal-title":"Vision Res"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2050-6511-16-S1-A76","article-title":"Asymmetric properties of rod cGMP Phosphodiesterase 6 (PDE6): structural and functional analysis","volume":"16","author":"Qureshi","year":"2015","journal-title":"BMC Pharmacol Toxicol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2193-1801-2-680","article-title":"Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells","volume":"2","author":"Dong","year":"2013","journal-title":"Springerplus"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)31474-1","article-title":"Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae","volume":"268","author":"Michaeli","year":"1993","journal-title":"J Biol Chem"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M601333200","article-title":"PDE7A1, a cAMP-specific phosphodiesterase, inhibits cAMP-dependent protein kinase by a direct interaction with C","volume":"281","author":"Han","year":"2006","journal-title":"J Biol Chem"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2014.10.008","article-title":"Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice","volume":"36","author":"Morales-Garcia","year":"2015","journal-title":"Neurobiol aging"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(02)00146-8","article-title":"Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans","volume":"15","author":"Gamanuma","year":"2003","journal-title":"Cell signalling"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0177","article-title":"The phosphodiesterase 8B gene rs4704397 is associated with thyroid function, risk of myocardial infarction, and body height: the Troms\u00f8 study","volume":"24","author":"Jorde","year":"2014","journal-title":"Thyroid"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2010.03.016","article-title":"Phosphodiesterase 8A (PDE8A) regulates excitation\u2013contraction coupling in ventricular myocytes","volume":"49","author":"Patrucco","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00941.2003","article-title":"Signal transduction by heme-containing PAS-domain proteins","volume":"96","author":"Gilles-Gonzalez","year":"2004","journal-title":"J Appl Physiol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04366.x","article-title":"Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours","volume":"77","author":"Rothenbuhler","year":"2012","journal-title":"Clin endocrinology"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2014.04.007","article-title":"Phosphodiesterase 9: insights from protein structure and role in therapeutics","volume":"106","author":"Singh","year":"2014","journal-title":"Life Sci"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1124\/mol.115.099747","article-title":"Structural asymmetry of phosphodiesterase-9A and a unique pocket for selective binding of a potent enantiomeric inhibitor","volume":"88","author":"Huang","year":"2015","journal-title":"Mol Pharmacol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.07.005","article-title":"The novel selective PDE9 inhibitor BAY 73\u20136691 improves learning and memory in rodents","volume":"55","author":"van der Staay","year":"2008","journal-title":"Neuropharmacology"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.2174\/156802610790411009","article-title":"Phosphodiesterase inhibitors as potential cognition enhancing agents","volume":"10","author":"Schmidt","year":"2010","journal-title":"Curr topics medicinal Chem"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(99)00171-7","article-title":"Isolation and characterization of PDE10A, a novel human 3\u2032, 5\u2032-cyclic nucleotide phosphodiesterase","volume":"234","author":"Loughney","year":"1999","journal-title":"Gene"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.17.2.147","article-title":"The potential therapeutic use of phosphodiesterase 10 inhibitors","volume":"17","author":"Kehler","year":"2007","journal-title":"Expert Opin Ther Patents"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M511468200","article-title":"cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11","volume":"281","author":"Gross-Langenhoff","year":"2006","journal-title":"J Biol Chem"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2032 s disease transgenic mice prior to the onset of motor symptoms","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"key":"B143","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1158\/1538-7445.AM2016-4736","article-title":"PDE10A overexpression in cancer cells and tumors as compared to normal cells and tissues","volume":"76","author":"Lindsey","year":"2016","journal-title":"Cancer Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1200\/jco.2014.32.3_suppl.503","article-title":"Phosphodiesterase 10, a novel target in colon cancer","volume":"32","author":"Russo","year":"2014","journal-title":"Am Soc Clin Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1158\/1538-7445.AM2014-1762","article-title":"Phosphodiesterase 10, a novel target for colorectal cancer therapeutics","volume":"74","author":"Lee","year":"2014","journal-title":"Cancer Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3702","article-title":"Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A","volume":"97","author":"Fawcett","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901441","article-title":"Phosphodiesterase 11: a brief review of structure, expression and function","volume":"18","author":"Makhlouf","year":"2006","journal-title":"Int J impotence Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2001.01866.x","article-title":"Genomic organization of the human phosphodiesterase PDE11A gene: evolutionary relatedness with other PDEs containing GAF domains","volume":"268","author":"Yuasa","year":"2001","journal-title":"Eur J Biochem"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0884","article-title":"Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors","volume":"69","author":"Horvath","year":"2009","journal-title":"Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.14-0248","article-title":"PDE4 and PDE5 regulate cyclic nucleotide contents and relaxing effects on carbachol-induced contraction in the bovine abomasum","volume":"77","author":"Kaneda","year":"2015","journal-title":"J Veterinary Med Science"},{"key":"B151","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1369\/jhc.5A6625.2005","article-title":"Expression of PDE11A in normal and Malignant human tissues","volume":"53","author":"D\u2019Andrea","year":"2005","journal-title":"J Histochem Cytochemistry"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1655","article-title":"Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer","volume":"96","author":"Faucz","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2914","article-title":"Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population","volume":"66","author":"Horvath","year":"2006","journal-title":"Cancer Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.3","article-title":"Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder","volume":"6","author":"MacMullen","year":"2016","journal-title":"Trans Psychiatry"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Res"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"J Histochem Cytochem"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142214","article-title":"Phosphodiesterase 10A (PDE10A): regulator of dopamine agonist-induced gene expression in the striatum","volume":"11","author":"Bonate","year":"2022","journal-title":"Cells"},{"key":"B158","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1007\/s12975-020-00819-8","article-title":"Phosphodiesterase 10A inhibition leads to brain region-specific recovery based on stroke type","volume":"12","author":"Birjandi","year":"2021","journal-title":"Transl Stroke Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/cells13141230","article-title":"Tepper MA. A novel PDE10A inhibitor for tourette syndrome and other movement disorders","volume":"13","author":"Marshall","year":"2024","journal-title":"Cells"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.600178","article-title":"PDE10A inhibitors-clinical failure or window into antipsychotic drug action","volume":"14","author":"Menniti","year":"2020","journal-title":"Front Neurosci"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.595769","article-title":"Phosphodiesterase 10A is tethered to a synaptic signaling complex in striatum","volume":"290","author":"Russwurm","year":"2015","journal-title":"J Biol Chem"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1002\/hipo.22128","article-title":"PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington\u2019s disease mouse model","volume":"23","author":"Giralt","year":"2013","journal-title":"Hippocampus"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00100","article-title":"The phosphodiesterase 10A inhibitor PF-2545920 enhances hippocampal excitability and seizure activity involving the upregulation of gluA1 and NR2A in post-synaptic densities","volume":"10","author":"Zhang","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"B165","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.2174\/138161211795049624","article-title":"PDE10A inhibitors: novel therapeutic drugs for schizophrenia","volume":"17","author":"Kehler","year":"2011","journal-title":"Curr Pharm design"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1124\/mol.65.2.267","article-title":"Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins","volume":"65","author":"Zoraghi","year":"2004","journal-title":"Mol Pharmacol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M800595200","article-title":"Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP","volume":"283","author":"Handa","year":"2008","journal-title":"J Biol Chem"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0700279104","article-title":"Structural insight into substrate specificity of phosphodiesterase 10","volume":"104","author":"Wang","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2004.10.004","article-title":"Structural basis for the activity of drugs that inhibit phosphodiesterases","volume":"12","author":"Card","year":"2004","journal-title":"Structure"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1021\/jm040217u","article-title":"The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases","volume":"48","author":"Manallack","year":"2005","journal-title":"J medicinal Chem"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1021\/jm900521k","article-title":"Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1 H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia","volume":"52","author":"Verhoest","year":"2009","journal-title":"J medicinal Chem"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.39.651","article-title":"Synthesis and platelet aggregation inhibitory activity of diphenylazole derivatives. I. Thiazole and imidazole derivatives","volume":"39","author":"Seko","year":"1991","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"B174","doi-asserted-by":"publisher","first-page":"pyw030","DOI":"10.1093\/ijnp\/pyw030","article-title":"Phosphodiesterase inhibition and regulation of dopaminergic frontal and striatal functioning: clinical implications","volume":"19","author":"Heckman","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0060-15.2015","article-title":"Selective effects of PDE10A inhibitors on striatopallidal neurons require phosphatase inhibition by DARPP-32","volume":"2","author":"Polito","year":"2015","journal-title":"eNeuro"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2016.20","article-title":"TAK-063, a PDE10A inhibitor with balanced activation of direct and indirect pathways, provides potent antipsychotic-like effects in multiple paradigms","volume":"41","author":"Suzuki","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.10.037","article-title":"Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy","volume":"102","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/nrm911","article-title":"Cyclic nucleotide research\u2014still expanding after half a century","volume":"3","author":"Beavo","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B179","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-58811-7_14","article-title":"PDE inhibitors for the treatment of schizophrenia","volume-title":"Phosphodiesterases: CNS Functions and Diseases","author":"Snyder","year":"2017"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"2011","journal-title":"Physiol Rev"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.1999.00963.x","article-title":"Striatum-and testis-specific phosphodiesterase PDE10A: Isolation and characterization of a rat PDE10A","volume":"266","author":"Fujishige","year":"1999","journal-title":"Eur J Biochem"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.12.7071","article-title":"Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A","volume":"96","author":"Soderling","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"J Neurosci"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2006.02.004","article-title":"Structure and dynamics of PKA signaling proteins","volume":"85","author":"Kim","year":"2006","journal-title":"Eur J Cell Biol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2006.04.013","article-title":"Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"B186","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neures.2009.05.005","article-title":"Colocalization of dopamine receptor subtypes with dopamine and cAMP-regulated phosphoprotein (DARPP-32) in rat brain","volume":"65","author":"Rajput","year":"2009","journal-title":"Neurosci Res"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/nn.2153","article-title":"Cell type\u2013specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs","volume":"11","author":"Bateup","year":"2008","journal-title":"Nat Neurosci"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/45251","article-title":"Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons","volume":"402","author":"Bibb","year":"1999","journal-title":"Nature"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.44.101802.121415","article-title":"DARPP-32: an integrator of neurotransmission","volume":"44","author":"Svenningsson","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.211904","article-title":"Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs","volume":"349","author":"Megens","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B191","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1254\/jphs.10R01FM","article-title":"Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission","volume":"114","author":"Nishi","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2005.03937.x","article-title":"PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats","volume":"21","author":"Rodefer","year":"2005","journal-title":"Eur J Neurosci"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(95)90294-5","article-title":"Modulation of calcium currents by a D1 dopaminergic protein kinase\/phosphatase cascade in rat neostriatal neurons","volume":"14","author":"Surmeier","year":"1995","journal-title":"Neuron"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80144-0","article-title":"Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit","volume":"16","author":"Roche","year":"1996","journal-title":"Neuron"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80798-9","article-title":"Beyond the dopamine receptor: the DARPP-32\/protein phosphatase-1 cascade","volume":"23","author":"Greengard","year":"1999","journal-title":"Neuron"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5378.838","article-title":"DARPP-32: regulator of the efficacy of dopaminergic neurotransmission","volume":"281","author":"Fienberg","year":"1998","journal-title":"Science"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/4516","article-title":"Protein phosphatase 1 modulation of neostriatal AMPA channels: regulation by DARPP-32 and spinophilin","volume":"2","author":"Yan","year":"1999","journal-title":"Nat Neurosci"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-24-10297.1998","article-title":"A dopamine\/D1 receptor\/protein kinase A\/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)\/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor","volume":"18","author":"Snyder","year":"1998","journal-title":"J Neurosci"},{"key":"B200","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1152\/jn.2000.83.5.2996","article-title":"D(1) dopamine receptor activation reduces GABA(A) receptor currents in neostriatal neurons through a PKA\/DARPP-32\/PP1 signaling cascade","volume":"83","author":"Flores-Hernandez","year":"2000","journal-title":"J Neurophysiol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666180309110629","article-title":"Phosphodiesterase 10 inhibitors-novel perspectives for psychiatric and neurodegenerative drug discovery","volume":"25","author":"Zagorska","year":"2018","journal-title":"Curr medicinal Chem"},{"key":"B202","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/jnnp.72.1.12","article-title":"Neuropsychiatry of the basal ganglia","volume":"72","author":"Ring","year":"2002","journal-title":"J Neurology Neurosurg Psychiatry"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1007\/BF03159935","article-title":"Pathology of Parkinson\u2019s disease: changes other than the nigrostriatal pathway","volume":"14","author":"Jellinger","year":"1991","journal-title":"Mol Chem neuropathology"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br J Pharmacol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04942.x","article-title":"Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain","volume":"103","author":"Liang","year":"2007","journal-title":"J neurochemistry"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease","volume":"5","author":"Giamp\u00e0","year":"2010","journal-title":"PLoS One"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington\u2019s disease models","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-11-0095","article-title":"Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt\/\u03b2-catenin\u2013mediated transcription in human breast tumor cells","volume":"4","author":"Tinsley","year":"2011","journal-title":"Cancer Prev Res"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1101\/gad.351350.123","article-title":"Haploinsufficiency of phosphodiesterase 10A activates PI3K\/AKT signaling independent of PTEN to induce an aggressive glioma phenotype","volume":"38","author":"Nuechterlein","year":"2024","journal-title":"Genes Dev"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.2174\/1381612820666140826114744","article-title":"Emerging biology of PDE10A","volume":"21","author":"Wilson","year":"2015","journal-title":"Curr Pharm Des"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1500","article-title":"Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer","volume":"7","author":"Fusco","year":"2018","journal-title":"Cancer Med"},{"key":"B212","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ajhg.2016.09.020","article-title":"Proteome-scale investigation of protein allosteric regulation perturbed by somatic mutations in 7,000 cancer genomes","volume":"100","author":"Shen","year":"2017","journal-title":"Am J Hum Genet"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.91","article-title":"PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4","volume":"29","author":"Kwon","year":"2010","journal-title":"Oncogene"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.858782","article-title":"Phosphorylation-dependent regulation of WNT\/beta-catenin signaling","volume":"12","author":"Shah","year":"2022","journal-title":"Front Oncol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"18951","DOI":"10.14670\/HH-18-951","article-title":"Loss of PDE10A is associated with metastasis of colon adenocarcinoma","author":"Arowa","year":"2025","journal-title":"Histol Histopathol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/ERC-15-0134","article-title":"Phosphodiesterase sequence variants may predispose to prostate cancer","volume":"22","author":"de Alexandre","year":"2015","journal-title":"Endocrine-related cancer"},{"key":"B217","doi-asserted-by":"publisher","first-page":"43894","DOI":"10.18632\/oncotarget.9707","article-title":"Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: a preliminary study","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007971","article-title":"Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity","volume":"93","author":"Zekeridou","year":"2019","journal-title":"Neurology"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1177\/10935266211012186","article-title":"Second report of PDE10A-BRAF fusion in pediatric spindle cell sarcoma with infantile fibrosarcoma-like morphology suggesting PDE10A-BRAF fusion is a recurrent event","volume":"24","author":"Hughes","year":"2021","journal-title":"Pediatr Dev Pathology"},{"key":"B220","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00007","article-title":"Novel PDE10A-BRAF fusion with concomitant NF1 mutation identified in an undifferentiated sarcoma of infancy with sustained response to trametinib","volume":"2","author":"Vairy","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"B221","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1158\/1538-7445.AM2016-4736","article-title":"Abstract 4736: PDE10A overexpression in cancer cells and tumors as compared to normal cells and tissues","volume":"76","author":"Lindsey","year":"2016","journal-title":"Cancer Res"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.122.322264","article-title":"PDE10A inactivation prevents doxorubicin-induced cardiotoxicity and tumor growth","volume":"133","author":"Chen","year":"2023","journal-title":"Circ Res"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4741","article-title":"Suppression of \u03b2-catenin\/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"B224","doi-asserted-by":"publisher","first-page":"9665","DOI":"10.3390\/ijms22189665","article-title":"Suppression of proliferation of human glioblastoma cells by combined phosphodiesterase and multidrug resistance-associated protein 1 inhibition","volume":"22","author":"Kopanitsa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.05.043","article-title":"Therapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors","volume":"230","author":"Mehta","year":"2019","journal-title":"Life Sci"},{"key":"B226","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1158\/1538-7445.AM2021-1213","article-title":"PDE10A as a novel target to suppress Wnt\/\u03b2-catenin signaling and other oncogenic pathways in ovarian cancer","volume":"81","author":"Barber","year":"2021","journal-title":"Cancer Res"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1530\/jrf.0.0590351","article-title":"Ovarian cAMP and cGMP fluctuations in the hamster during the oestrous cycle","volume":"59","author":"Hubbard","year":"1980","journal-title":"J Reprod Fertil"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.08.028","article-title":"A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia","volume":"204","author":"Macek","year":"2019","journal-title":"Schizophr Res"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1161\/res.129.suppl_1.MP265","article-title":"Abstract MP265: the role of phosphodiesterase 10a in tumor growth and doxorubicin-induced cardiotoxicity","volume":"129","author":"Chen","year":"2021","journal-title":"Circ Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:16:55Z","timestamp":1760588215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1669157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":229,"alternative-id":["10.3389\/fonc.2025.1669157"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1669157","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"article-number":"1669157"}}